View Older Stories View More Recent Stories

Feb 29, 2016 07:03AM Bristol-Myers Squibb Selects Veeva Vault RIM Solutions
Feb 26, 2016 07:16AM Bristol-Myers Squibb (BMY) Announces Two Positive CHMP Opinions for Opdivo for Treatment of NSCLC
Feb 26, 2016 07:13AM Bristol-Myers Squibb Receives Two Positive CHMP Opinions for Opdivo® (nivolumab) for Patients with Previously Treated Advanced Non-Squamous Non-Small Cell Lung Cancer and Renal Cell Carcinoma
Feb 22, 2016 10:47AM Bristol-Myers Squibb (BMY) Announces Completion of HIV R&D Portfolio Sale to ViiV Healthcare
Feb 22, 2016 10:45AM Bristol-Myers Squibb Completes Previously Announced Sale of its HIV R&D Portfolio to ViiV Healthcare
Feb 22, 2016 06:59AM Data Presented at APASL from First Completed Phase 3 Trial of All-oral Chronic Hepatitis C Regimen in Chinese Patient Population Shows Daclatasvir and Asunaprevir DUAL Therapy Demonstrated High Cure R
Feb 16, 2016 07:16AM Bristol-Myers Squibb (BMY), Dana-Farber Cancer Institute Enter I-O RPM Program Collaboration
Feb 16, 2016 06:59AM Bristol-Myers Squibb and Dana-Farber Cancer Institute Enter Into a Collaboration Agreement as Part of U.S. Immuno-Oncology Rare Population Malignancy Research Program
Feb 5, 2016 12:48PM Bristol-Myers Squibb (BMY) Receives FDA Approval for Expanded Daklinza Indication in Genotype 1, 3 HCV
Feb 5, 2016 12:47PM U.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C
Feb 3, 2016 10:00AM Bristol-Myers Squibb to Take Part in Leerink Swann Global Healthcare Conference
Feb 1, 2016 09:00AM Bristol-Myers Squibb Foundation Awards Eight Grants Totaling Nearly $11.5M to Make Lung and Skin Cancer Screening, Care More Accessible in High-Risk U.S. Communities
Feb 1, 2016 06:56AM Portola Pharma (PTLA) Enters Licensing Agreements for Investigational Agent Andexanet in Japan (BMY) (PFE)
Feb 1, 2016 06:55AM Bristol-Myers Squibb and Pfizer Sign Collaboration with Portola Pharmaceuticals to Develop and Commercialize Investigational Andexanet Alfa in Japan
Jan 29, 2016 07:49AM Bristol-Myers Squibb (BMY), AbbVie (ABBV) Announce Receipt of Positive CHMP Opinion for Empliciti as Multiple Myeloma Treatment
Jan 29, 2016 07:48AM Bristol-Myers Squibb and AbbVie Receive Positive CHMP Opinion for Investigational Antibody, Empliciti (elotuzumab), for the Treatment of Multiple Myeloma in Patients Who Have Received at Least One Pri
Jan 28, 2016 12:44PM Bristol-Myers Squibb (BMY) Announces Receipt of EC Approval for Daklinza in Certain HCV Genotypes
Jan 28, 2016 12:41PM European Commission Approves Daklinza (daclatasvir) for the Treatment of Genotype 1, 3 and 4 Chronic Hepatitis C Patients with HIV Coinfection, Advanced Cirrhosis and Post-liver Transplant Recurrence
Jan 28, 2016 07:11AM Bristol-Myers Squibb (BMY) Announces Early Stoppage of Opdivo Phase 3 in SCCHN
Jan 28, 2016 06:59AM Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2015 Financial Results
Jan 28, 2016 06:59AM CheckMate -141, a Pivotal Phase 3 Opdivo (nivolumab) Head and Neck Cancer Trial, Stopped Early
Jan 25, 2016 06:59AM REPEAT/ Bristol-Myers Squibb’s Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen Receives Expanded FDA Approval in Unresectable or Metastatic Melanoma Across BRAF Status1
Jan 25, 2016 06:15AM Bristol-Myers Squibb (BMY) Receives FDA Approval for Expanded Opdivo + Yervoy Combo Indication
Jan 23, 2016 06:36PM Bristol-Myers Squibb’s Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen Receives Expanded FDA Approval in Unresectable or Metastatic Melanoma Across BRAF Status1
Jan 5, 2016 10:00AM Bristol-Myers Squibb to Present at J.P. Morgan Healthcare Conference
Dec 23, 2015 08:01AM Seattle Genetics (SGEN), Bristol-Myers Squibb (BMY) Initiate ADCETRIS + Opdivo Phase 1/2 in DLBCL
Dec 23, 2015 08:00AM Seattle Genetics and Bristol-Myers Squibb Announce Initiation of Phase 1/2 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) in Combination with Opdivo® (Nivolumab) in Relapsed or Refractory Non-Hod
Dec 18, 2015 06:35AM ViiV Healthcare to Acquire Bristol-Myers Squibb's (BMY) Investigational HIV Medicines Pipeline
Dec 18, 2015 02:01AM Bristol-Myers Squibb to Sell its HIV R&D Portfolio to ViiV Healthcare
Dec 17, 2015 04:30PM BMS and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute Enter Into a Collaboration Agreement as Part of U.S. Immuno-O
Dec 14, 2015 07:01AM Bristol-Myers Squibb (BMY), UCLA Enter I-O RPM Research Program Collaboration
Dec 14, 2015 06:59AM Bristol-Myers Squibb and UCLA Enter into a Collaboration Agreement as Part of U.S. Immuno-Oncology Rare Population Malignancy Research Program
Dec 11, 2015 11:40AM Bristol-Myers Squibb to Announce Results for Fourth Quarter, Full Year 2015 on January 28
Dec 10, 2015 04:25PM Bristol-Myers Squibb (BMY) , Pfizer (PFE) Announce Encouraging Post-Hoc Data from Phase 3 AMPLIFY in VTE
Dec 10, 2015 04:15PM AMPLIFY Post-Hoc Early Time Course Analysis Evaluated Recurrent Venous Thromboembolism (VTE), VTE-Related Death and Major Bleeding in Deep Vein Thrombosis and Pulmonary Embolism Patients Treated with
Dec 8, 2015 04:15PM Bristol-Myers Squibb Completes Previously Announced Acquisition of Cardioxyl Pharmaceuticals, Inc.
Dec 8, 2015 04:11PM Bristol-Myers Squibb (BMY) Enters Research Collaboration with Princeton University Dept. of Chemistry
Dec 8, 2015 04:10PM Bristol-Myers Squibb Establishes Center for Molecular Synthesis in New Collaboration with Princeton University
Dec 8, 2015 04:05PM Bristol-Myers Squibb Announces Dividend Increase
Dec 5, 2015 08:15AM New Longer-Term Data for Empliciti (elotuzumab) Showed a Continued Progression-Free Survival Benefit in Patients with Relapsed or Refractory Multiple Myeloma
Dec 4, 2015 08:00AM Bristol-Myers Squibb Receives Multiple Myeloma Research Foundation’s 2015 Collaborator Award
Dec 1, 2015 09:00AM Bristol-Myers Squibb Foundation Marks World AIDS Day with Grants Totaling More than $3.5M for HIV and Cervical and Breast Cancer Programs in Africa
Nov 30, 2015 03:14PM Bristol-Myers Squibb and AbbVie Receive FDA Approval of Empliciti™ (elotuzumab) for the Treatment of Patients with Multiple Myeloma Who Have Received One to Three Prior Therapies
Nov 30, 2015 06:59AM Bristol-Myers Squibb to Present New Data across Multiple Blood Cancers at the 57th Annual Meeting & Exposition of the American Society of Hematology
Nov 27, 2015 03:29PM Bristol-Myers Squibb Announces Regulatory Update for Opdivo (nivolumab) in Advanced Melanoma
Nov 24, 2015 06:59AM European Commission Approves Reconciliation of Indications for nivolumab Under the Opdivo® European Marketing Authorization Application
Nov 24, 2015 06:55AM Bristol-Myers Squibb Announces U.S. Food and Drug Administration Approval for Opdivo (nivolumab) as a Single Agent for the Treatment of Patients with Previously Untreated BRAF Wild-Type Advanced Melan
Nov 23, 2015 07:23PM Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab), the Only Treatment to Deliver Significant Overall Survival in Advanced Renal Cell Carcinoma vs. a Standard of Care, in Patients Who H
Nov 18, 2015 12:00PM New Long-Term Data on Opdivo and the Opdivo + Yervoy Regimen Shows Survival Benefit Across Lines of Therapy in Advanced Melanoma
Nov 16, 2015 05:03PM U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application for Opdivo (nivolumab) in Patients with Advanced Renal Cell Carcinoma
View More Recent Stories View Older Stories